{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:7940"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:7940","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"The role of CD8+ regulatory T cells in anti-tumour immune responses in Hepatocellular Carcinoma","abstract":"Tumour specific effector T-cells can be detected in the blood and tumours of patients with hepatocellular carcinoma (HCC) but fail to mount effective immune responses. Attempts to amplify anti-tumour immune responses using immunotherapy show promise, but are hampered by the presence of suppressive regulatory T-cells (Treg) that inhibit anti-tumour immune responses. Many different subsets of Treg have since been identified including regulatory T-cells expressing the surface marker CD8 (CD8\\(^+\\)Treg). A set of experiments was designed in an attempt to increase our understanding on how CD8\\(^+\\)Treg may disrupt anti-tumour response and by what mechanisms they are induced. CD8\\(^+\\)Treg was analysed by isolation of liver-derived T-cells from human HCC. Monocyte-derived dendritic cells (moDC) matured with tumour tissue conditioned medium were used to assess they potential to induce CD8\\(^+\\)Treg. CD8\\(^+\\)Treg infiltrating HCC demonstrated a suppressive phenotype. The co-culture of naïve CD8\\(^+\\)T-cells with tumour-conditioned moDC induces a population of CD8\\(^+\\)Treg through an IDO dependent mechanism. This population of induced T-cells was able to suppress via the CD39-adenosine pathway. The findings of the mechanisms involved in the induction of CD8\\(^+\\)Treg by DC and the involvement of CD39 in the suppressive capacity of these novel T-cells, may guide the development of future immunotherapeutic in HCC.","abstract_html":"Tumour specific effector T-cells can be detected in the blood and tumours of patients with hepatocellular carcinoma (HCC) but fail to mount effective immune responses. Attempts to amplify anti-tumour immune responses using immunotherapy show promise, but are hampered by the presence of suppressive regulatory T-cells (Treg) that inhibit anti-tumour immune responses. Many different subsets of Treg have since been identified including regulatory T-cells expressing the surface marker CD8 (CD8<span class=\"etd-inline-math\"><sup>+</sup></span>Treg). A set of experiments was designed in an attempt to increase our understanding on how CD8<span class=\"etd-inline-math\"><sup>+</sup></span>Treg may disrupt anti-tumour response and by what mechanisms they are induced. CD8<span class=\"etd-inline-math\"><sup>+</sup></span>Treg was analysed by isolation of liver-derived T-cells from human HCC. Monocyte-derived dendritic cells (moDC) matured with tumour tissue conditioned medium were used to assess they potential to induce CD8<span class=\"etd-inline-math\"><sup>+</sup></span>Treg. CD8<span class=\"etd-inline-math\"><sup>+</sup></span>Treg infiltrating HCC demonstrated a suppressive phenotype. The co-culture of naïve CD8<span class=\"etd-inline-math\"><sup>+</sup></span>T-cells with tumour-conditioned moDC induces a population of CD8<span class=\"etd-inline-math\"><sup>+</sup></span>Treg through an IDO dependent mechanism. This population of induced T-cells was able to suppress via the CD39-adenosine pathway. The findings of the mechanisms involved in the induction of CD8<span class=\"etd-inline-math\"><sup>+</sup></span>Treg by DC and the involvement of CD39 in the suppressive capacity of these novel T-cells, may guide the development of future immunotherapeutic in HCC.","abstract_has_math":true,"creators":["Li, Ka-Kit"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-07","date_published":"2018-07","updated_at":"2026-11-19T09:29:41Z","subjects":["QR180 Immunology","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/7940/1/Li18PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A7940","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Li, Ka-Kit"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2018-07"]},{"key":"dc:date.issued","label":"Date","values":["2018-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/7940/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["QR180 Immunology","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/7940/1/Li18PhD.pdf","http://etheses.bham.ac.uk//id/eprint/7940/2/Decl_IS_Li18PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Tumour specific effector T-cells can be detected in the blood and tumours of patients with hepatocellular carcinoma (HCC) but fail to mount effective immune responses. Attempts to amplify anti-tumour immune responses using immunotherapy show promise, but are hampered by the presence of suppressive regulatory T-cells (Treg) that inhibit anti-tumour immune responses. Many different subsets of Treg have since been identified including regulatory T-cells expressing the surface marker CD8 (CD8\\(^+\\)Treg). A set of experiments was designed in an attempt to increase our understanding on how CD8\\(^+\\)Treg may disrupt anti-tumour response and by what mechanisms they are induced. CD8\\(^+\\)Treg was analysed by isolation of liver-derived T-cells from human HCC. Monocyte-derived dendritic cells (moDC) matured with tumour tissue conditioned medium were used to assess they potential to induce CD8\\(^+\\)Treg. CD8\\(^+\\)Treg infiltrating HCC demonstrated a suppressive phenotype. The co-culture of naïve CD8\\(^+\\)T-cells with tumour-conditioned moDC induces a population of CD8\\(^+\\)Treg through an IDO dependent mechanism. This population of induced T-cells was able to suppress via the CD39-adenosine pathway. The findings of the mechanisms involved in the induction of CD8\\(^+\\)Treg by DC and the involvement of CD39 in the suppressive capacity of these novel T-cells, may guide the development of future immunotherapeutic in HCC."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["The role of CD8+ regulatory T cells in anti-tumour immune responses in Hepatocellular Carcinoma"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Li, Ka-Kit"],"dc:date":["2018-07"],"dc:date.issued":["2018-07"],"dc:description.abstract":["Tumour specific effector T-cells can be detected in the blood and tumours of patients with hepatocellular carcinoma (HCC) but fail to mount effective immune responses. Attempts to amplify anti-tumour immune responses using immunotherapy show promise, but are hampered by the presence of suppressive regulatory T-cells (Treg) that inhibit anti-tumour immune responses. Many different subsets of Treg have since been identified including regulatory T-cells expressing the surface marker CD8 (CD8\\(^+\\)Treg). A set of experiments was designed in an attempt to increase our understanding on how CD8\\(^+\\)Treg may disrupt anti-tumour response and by what mechanisms they are induced. CD8\\(^+\\)Treg was analysed by isolation of liver-derived T-cells from human HCC. Monocyte-derived dendritic cells (moDC) matured with tumour tissue conditioned medium were used to assess they potential to induce CD8\\(^+\\)Treg. CD8\\(^+\\)Treg infiltrating HCC demonstrated a suppressive phenotype. The co-culture of naïve CD8\\(^+\\)T-cells with tumour-conditioned moDC induces a population of CD8\\(^+\\)Treg through an IDO dependent mechanism. This population of induced T-cells was able to suppress via the CD39-adenosine pathway. The findings of the mechanisms involved in the induction of CD8\\(^+\\)Treg by DC and the involvement of CD39 in the suppressive capacity of these novel T-cells, may guide the development of future immunotherapeutic in HCC."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/7940/1/Li18PhD.pdf","http://etheses.bham.ac.uk//id/eprint/7940/2/Decl_IS_Li18PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/7940/"],"dc:subject":["QR180 Immunology","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public","staffonly"],"dc:title":["The role of CD8+ regulatory T cells in anti-tumour immune responses in Hepatocellular Carcinoma"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:29:41Z"}